金币
UID11432
帖子
主题
积分18972
注册时间2011-12-29
最后登录1970-1-1
听众
性别保密
|
发表于 2020-9-21 20:36:09
|
显示全部楼层
本帖最后由 roadman 于 2020-9-21 19:39 编辑
FDA指南:无菌工艺生产的无菌药品——CGMP有要求:
When appropriate, time limits must be established for each phase of aseptic processing (§ 211.111). Time limits should include, for example, the period between the start of bulk product compounding and its sterilization, filtration processes, product exposure while on the processing line, and storage of sterilized equipment, containers and closures. The time limits established for the various production phases should be supported by data. Bioburden and endotoxin load should be assessed when establishing time limits for stages such as the formulation processing stage.
凡合适,必须制定无菌生产的各个阶段的时间限制(§ 211.111)。时间限制应当包括,例如,在半成品混合的起始到灭菌之间的阶段,过滤过程,在生产线上产品的敞露,灭过菌的设备,容器和盖塞的储存。各个生产阶段的时间限制的制定应当是要有数据支持的。在为各个阶段如配料工艺阶段制定时间限制时,应当对生物载荷量和内毒素载荷量进行评估。
无菌医疗器械的要求应该与药品类似,道理是相同。 |
|